ACCESS Newswire

NOSIBLE Raises $1 Million Pre-Seed, Welcomes Industry Veteran Axel Hörger

Share

Funding led by Atlantica Ventures supports the launch of nosible.ai, an arena of hyperspecialized AI agents that automate time-intensive tasks in asset management.

SAN FRANCISCO, CA AND NEW YORK, NY / ACCESS Newswire / March 26, 2025 / NOSIBLE, an upcoming AI startup, today announces it has secured $1 million in pre-seed funding led by Atlantica Ventures, alongside additional strategic investments from existing customers. The funding will support NOSIBLE in launching its growth marketing efforts, scaling its sales operations, and accelerating its go-to-market strategy.

Founded by Stuart Reid, a computer scientist and quantitative analyst with over a decade of experience building large-scale AI systems, NOSIBLE is on a mission to become the leading AI provider to asset managers. After working with existing technology for many years Stuart and Matthew Dicks, a founding engineer at NOSIBLE, made a remarkable discovery - a novel solution to one of AI's most challenging puzzles, approximate nearest neighbors.

NOSIBLE's solution is uniquely optimized for disk, supports native pre-filtering, compression, streaming, bulk querying, and even real-time hyperparameter tuning. These characteristics combine to create a solution that is 100x cheaper than the current state-of-the-art in large-scale search. Recognizing search as a scaling law, NOSIBLE's innovation unlocks smarter AI agents because they search 100x more.

"Our discovery changes the AI equation," said Stuart Reid, Founder and CEO of NOSIBLE. "Our index operates at 1/100th the cost of current methods and uniquely supports real-time hyperparameter tuning, allowing it to dynamically adapt to more complex searches - similar to how OpenAI pioneered the use of test-time compute."

Speaking on their investment, Ik Kanu, Founding Partner at Atlantica Ventures adds, "We invested in NOSIBLE because we saw a small, focused team that was deeply knowledgeable in quantitative finance, ML, and computer science, building their own infrastructure to power a low-cost, agentic platform with intelligent workflows. This unique blend of finance and tech expertise allows NOSIBLE to deliver highly specialized value for small to large asset managers with impressive capital efficiency - it's exactly the kind of focused innovation we look for."

Joining NOSIBLE at this critical stage is industry veteran Axel Hörger, who comes on board as Advisor. Hörger brings nearly three decades of experience in executive leadership roles at leading financial institutions, including Lombard International, UBS, and Goldman Sachs. His extensive network and deep expertise in capital markets and next-generation digitalization will be pivotal in accelerating NOSIBLE's influence.

"NOSIBLE's innovation unlocks exciting new opportunities by enabling AI agents to perform more searches, enhancing the depth and accuracy of their results", explained Hörger. "The team has developed a technology with the potential to reshape AI analytics entirely, and I'm thrilled to join NOSIBLE at this important stage and leverage my experience to help drive the next phase of growth."

Alongside the new funding, the company has released nosible.ai - a competitive arena featuring hyperspecialized AI agents designed to deliver targeted and accurate responses to users' questions. Unlike generalized "God models" popularized by large AI labs, each nosible.ai agent focuses exclusively on performing one task exceptionally well, improving continuously through extensive search interactions.

NOSIBLE's core thesis is straightforward: the more its AI agents search, the smarter they become. For instance, its research agent can quickly analyze data in minutes, which traditionally requires 20 hours. By drastically reducing the cost of web-scale search, NOSIBLE believes its agents will deliver significantly deeper insights.

Reid concludes, "nosible.ai agents empower asset managers to do the impossible. With lower search costs, our agents can deliver unprecedented analytical depth."

NOSIBLE is redefining expectations for AI agents and setting new standards for web-scale search, paving the way for future innovations.

- ENDS-

For additional information on NOSIBLE or interview requests, please contact Timileyin Omilana at timileyin@wimbart.com

About NOSIBLE

Founded in 2020, NOSIBLE is an emerging AI startup, offering two core products: a powerful search engine API that provides businesses with real-time and historical data insights, and nosible.ai, a consumer-facing platform featuring hyperspecialized AI agents designed to streamline asset management tasks.

SOURCE: NOSIBLE INC



View the original press release on ACCESS Newswire

NOSIBLE INC

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release

Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release

Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen

Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release

SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan

Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release

On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI

PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release

MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye